All articles tagged with #spinal fluid test
New guidelines for diagnosing multiple sclerosis (MS) allow for earlier and more accurate detection, even before symptoms appear, by using advanced imaging techniques and updated criteria, which can lead to earlier treatment and better outcomes.
Actor Michael J. Fox has promoted a new spinal fluid test that can detect Parkinson's in living people, calling it "one of the most significant Parkinson's breakthroughs in decades." The test is "remarkably accurate" and can allow for diagnosis before symptoms arise, as well as tracking how biological factors may impact the risk, onset, and progression of the disease. Fox, who suffers from Parkinson's, said the test marks a new era in Parkinson's research. The disease, which affects approximately 500,000 Americans, currently has no cure.
The Parkinson's Progression Markers Initiative (PPMI) and The Michael J. Fox Foundation have discovered a spinal fluid test that can objectively detect Parkinson's in the cells of living people, allowing scientists to unlock some of Parkinson’s deepest-held secrets. The test is remarkably accurate and will allow for earlier diagnosis and monitoring, as well as the potential to prevent the disease altogether. Michael J. Fox, who was diagnosed with Parkinson's at age 29, emphasizes the importance of study volunteers in making this breakthrough possible and encourages those at risk to participate in clinical trials.
A new study sponsored by the Michael J. Fox Foundation has found that a test of spinal fluid can predict who is likely to develop Parkinson's disease years before symptoms appear. The test, called the alpha-synuclein seed amplification assay, uses a patient's spinal fluid to detect synuclein pathology, one of the two biological hallmarks of Parkinson’s. While the test doesn't replace an expert diagnosis, it could shape how and when Parkinson's is diagnosed and influence drug development and clinical care.
A new study sponsored by The Michael J. Fox Foundation has found that a test of spinal fluid can predict who is likely to develop Parkinson's disease years before symptoms first appear. The test, called the alpha-synuclein seed amplification assay, uses a patient's spinal fluid to detect synuclein pathology, one of the two biological hallmarks of Parkinson’s. While the test doesn't replace an expert diagnosis, it has the potential to shape how and when Parkinson's is diagnosed and could impact drug development and clinical care.